UK-based Huntsworth has acquired New Jersey’s Nucleus Global, a top medical specialist communications operation with more than 800 staffers in 14 offices throughout the world.
Launched in 1986, Nucleus handles scientific event management, publications, clinical trial support, medical education, external expert outreach, patient engagement, internal communications/training and digital programming.
Paul Taaffe, CEO of Huntsworth, told O’Dwyer’s the deal creates “one of the most powerful combinations in medical communications, which is a huge growth area as drug development becomes increasingly high science to meet the demand for more and more personalized medicine.”
Nucleus joins Huntsworth’s healthcare operating units of Huntsworth, MediStrava, Evoke Group and The Creative Engagement Group
“We will have more experts, across more therapeutic areas, across more countries than anybody else and that translates to creating more evidence around both the science and the economics for drug trials and drug launches,” said Taaffe, “That’s a big deal for the pharma and biotech industries.”
Nucleus is Huntsworth’s second acquisition since it went private under the ownership of equity firm Clayton, Dubilier & Rice.
“For our healthcare communication experts, mostly in Evoke Kyne, the addition of Nucleus means access to even more scientific expertise in both disease awareness and drug launch,” said Taaffe. “To have more than 300 advanced degree colleagues, mostly PhDs is an enormous point of differentiation.”
Nucleus founder/chair Stephen Cameron will continue to lead the firm and join Huntsworth’s board.